Randomized, Double-blinded, Placebo-controlled, Single Center, and Prospective Phase II Clinical Trial to Analyze the Effects of Antioxidant Agents on DNA Double-strand Breaks in Patients After Radiation-based Cardiac Examinations
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Focus of the Study: DNA Damage Due to Medical Diagnostic X-ray
- Sponsor
- University of Zurich
- Enrollment
- 102
- Locations
- 1
- Primary Endpoint
- Change in the number of DNA double-strand breaks under influence of antioxidant agents vs. placebo
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
Trial with medicinal products
Recent studies revealed that radiation-based procedures in patients may lead to DNA double-strand breaks in human blood lymphocytes. Additionally, ex vivo studies with human blood lymphocytes have shown a protective effect of antioxidant agents which have been described to decrease the number of DNA double-strand breaks.
This study represents a prospective, double-blinded, randomized, single center, and placebo-controlled phase II clinical trial which analyzes the capability of antioxidant agents to decrease the number of DNA double-strand breaks in human blood lymphocytes in patients undergoing radiation-based cardiac examinations (30 patients with high-dose radiation exposure, 30 patients with low-dose radiation exposure, and 30 subjects without radiation exposure).
A protective effect of antioxidant drugs in patients undergoing radiation-based examinations could therefore change patient management and would provide an important clinical impact.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Change in the number of DNA double-strand breaks under influence of antioxidant agents vs. placebo
Time Frame: Baseline blood draw before radiation exposure and follow-up blood draw approx. 30 minutes after radiation exposure
Potential change (before and after radiation exposure) in the number of DNA double-strand breaks under the influence of n-acetylcystein or ascorbic acid will be measured by qualitative and quantitative immunofluorescence studies (immunofluorescence microscopy and FACS analysis) and will be compared to study patients administered with placebo (using the same quantifiaction tools).
Secondary Outcomes
- Change in the number of DNA double-strand breaks between n-acetylcysteine and ascorbic acid(Baseline blood draw before radiation exposure and follow-up blood draw approx. 30 minutes after radiation exposure)
- Change in the number of DNA double-strand breaks between no, low, and high radiation exposure(Baseline blood draw before radiation exposure and follow-up blood draw approx. 30 minutes after radiation exposure)